Anbio Biotechnology Cl A (NNNN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | |
| Cash Flows From Operating Activities | ||||
| Net Income | 6,404 | 2,373 | 2,254 | 10,011 |
| Accounts receivable | -2,591 | 820 | -1,885 | 718 |
| Accounts payable and accrued liabilities | -1,625 | 798 | -581 | -482 |
| Other Working Capital | -13,211 | 45 | -1,204 | -5,530 |
| Other Operating Activity | 4,284 | -1,955 | 2,315 | -268 |
| Operating Cash Flow | $-6,739 | $2,080 | $898 | $4,449 |
| Cash Flows From Investing Activities | ||||
| Purchase Of Investment | -19,420 | -35,466 | -18,544 | -16,090 |
| Sale Of Investment | 15,218 | 35,803 | 20,274 | 14,562 |
| Investing Cash Flow | $-4,203 | $337 | $1,730 | $-1,528 |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | 7,230 | N/A | N/A | N/A |
| Other Financing Activity | -283 | -345 | -43 | 0 |
| Financing Cash Flow | $6,948 | $-345 | $-43 | $N/A |
| Beginning Cash Position | 11,761 | 9,688 | 7,102 | 4,181 |
| End Cash Position | 7,767 | 11,761 | 9,688 | 7,102 |
| Net Cash Flow | $-3,994 | $2,073 | $2,586 | $2,921 |
| Free Cash Flow | ||||
| Operating Cash Flow | -6,739 | 2,080 | 898 | 4,449 |
| Free Cash Flow | -6,739 | 2,080 | 898 | 4,449 |